Clinical Pharmacokinetics

, Volume 29, Issue 3, pp 172–191 | Cite as

Clinical Relevance of Drug Interactions with Lithium

  • Patrick R. Finley
  • M. Dhyanne Warner
  • Cecilia A. Peabody
Review Article Pharmacokinetic Drug Interactions

Summary

Although lithium continues to be regarded as the treatment of choice for bipolar disorders, the clinical use of this mood stabiliser is associated with an extremely narrow therapeutic range. Relatively minor increases in serum concentrations may induce serious adverse sequelae, and concentrations within the therapeutic range may result in toxic reactions. The safety of combining lithium with other medications, therefore, is a major concern, and extensive clinical experience has served to identify several significant drug interactions.

Lithium removal from the body is achieved almost exclusively via renal means. As a result, any medication that alters glomerular filtration rates or affects electrolyte exchange in the nephron may influence the pharmacokinetic disposition of lithium. Concomitant use of diuretics has long been associated with the development of lithium toxicity, but the risk of significant interactions varies with the site of pharmacological action of the diuretic in the renal tubule. Thiazide diuretics have demonstrated the greatest potential to increase lithium concentrations, with a 25 to 40% increase in concentrations often evident after initiation of therapy. Osmotic diuretics and methyl xanthines appear to have the opposite effect on lithium clearance and have been advocated historically as antidotes for lithium toxicity. Loop diuretics and potassium-sparing agents have minor variable effects.

Nonsteroidal anti-inflammatory drugs (NSAIDs) have also been associated with lithium toxicity, although the relative interactive potential of specific NSAIDs is difficult to determine. Small prospective studies have demonstrated large interindividual differences in lithium clearance values associated with different NSAIDs. A growing body of evidence also suggests that ACE inhibitors may impair lithium elimination, but further investigations are needed to identify patients at risk.

Anecdotal reports have linked numerous medications with the development of neurotoxicity without an apparent effect on the pharmacokinetic disposition of lithium. Antipsychotics, anticonvulsants and calcium antagonists have all been implicated in a sufficient number of case reports to warrant concern. As these medications have all been commonly coadministered with lithium, the relative risk of serious interactions appears to be quite low, but caution is advised.

Keywords

Lithium Adis International Limited Amiloride Neuroleptic Malignant Syndrome Lithium Concentration 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jefferson JW. Lithium: the present and future. J Clin Psychiatry 1995; 56: 41–8Google Scholar
  2. 2.
    Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349–52PubMedGoogle Scholar
  3. 3.
    Corcoran AC, Taylor RD, Page IH. Lithium poisoning from the use of salt substitutes. JAMA 1949; 139: 685–8Google Scholar
  4. 4.
    Schou M, Baastrup PC. Lithium treatment of manic-depressive disorder: dosage and control. JAMA 1967; 201: 696–8PubMedGoogle Scholar
  5. 5.
    Singer I. Lithium in mania. Clin Pharmacol Ther 1970; 11: 168–87Google Scholar
  6. 6.
    Meltzer HL. Mode of action of lithium in affective disorders: an influence on intracellular calcium functions. Pharmacol Toxicol 1990; 66 Suppl. 3: 84–99PubMedGoogle Scholar
  7. 7.
    Holstein-Rathlou N-H. Lithium transport across biological membranes. Kidney Int 1990; 28 Suppl.: S4–9Google Scholar
  8. 8.
    Price LH, Charney DS, Delgado PL, et al. Lithium and serotonin function: implication for the serotonin hypothesis of depression. Psychopharmacology 1990: 100: 3–12PubMedGoogle Scholar
  9. 9.
    Odagaki Y, Koyama Y, Yamashita I. Lithium and serotonergic neural transmission: a review of pharmacological and biochemical aspects in animal studies. Lithium 1992; 3: 95–107Google Scholar
  10. 10.
    Risby ED, Hsiao JK, Mahji HK, et al. The mechanism of lithium action. II. Effects on adenyl cyclase activity and beta adrenergic receptor binding in normal subjects. Arch Gen Psychiatry 1991; 48: 513–24PubMedGoogle Scholar
  11. 11.
    Dilsaver SC. Lithium’s effects on muscarinic receptor binding parameters: a relationship to therapeutic efficacy? Biol Psychiatry 1984; 19: 1551–65PubMedGoogle Scholar
  12. 12.
    Baraban J. Toward a crystal-clear view of lithium’s site of action. Proc Natl Acad Sci USA 1994; 91: 5738–9PubMedGoogle Scholar
  13. 13.
    Coppen A, Abou-Saleh M, Millen P, et al. Decreasing lithium dosage reduces morbidity and side effects during prophylaxis. J Affect Disord 1983; 5: 353–62PubMedGoogle Scholar
  14. 14.
    Gelenberg AJ, Wojcik JD, Falk WE, et al. Effects of lithium on the kidney. Acta Psychiatr Scand 1987; 75: 29–34PubMedGoogle Scholar
  15. 15.
    Hestbeck J, Hansen HE, Amdisen A, et al. Chronic renal lesions following long term treatment with lithium. Kidney Int 1977; 12: 305–13Google Scholar
  16. 16.
    Perry PJ. Lithium nephrotoxicity. Drug Intell Clin Pharm 1982; 16: 740–4PubMedGoogle Scholar
  17. 17.
    Kincaid-Smith P, Burrows GD, Davies BM, et al. Renal biopsy findings in lithium and pre-lithium patients. Lancet 1979; 2: 700–1PubMedGoogle Scholar
  18. 18.
    Lokkegaard H, Anderson NF, Henriksen E, et al. Renal function in 153 manic-depressive patients treated with lithium for more than five years. Acta Psychiatr Scand 1985; 71: 347–55PubMedGoogle Scholar
  19. 19.
    Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489–93PubMedGoogle Scholar
  20. 20.
    Hammond CM. Single daily dosage of lithium carbonate. Ann Pharmacother 1994; 28: 472–3PubMedGoogle Scholar
  21. 21.
    Carson SW. Lithium. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver: Applied Therapeutics, 1990: 34-1–34-26Google Scholar
  22. 22.
    Jermain DM, Crismon ML, Mertin ES. Population pharmacokinetics of lithium. Clin Pharm 1991; 10: 376–81PubMedGoogle Scholar
  23. 23.
    Price LH, Heninger GR. Lithium in the treatment of mood disorders. N Engl J Med 1994; 331: 591–8PubMedGoogle Scholar
  24. 24.
    Koomans HA, Boer WH, Dorhout Mees EJ. Evaluation of lithium clearance as a marker of proximal tubule sodium handling. Kidney Int 1989; 36: 2–12PubMedGoogle Scholar
  25. 25.
    Hayslett JP, Kashgarian M. A micropuncture study of the renal handling of lithium. Pflugers Arch 1979; 380: 159–63PubMedGoogle Scholar
  26. 26.
    Okusa MD, Crystal LJ. Clinical manifestations and management of lithium intoxication. Am J Med 1994; 97: 383–9PubMedGoogle Scholar
  27. 27.
    Kamper AL, Strandgaard S, Holstein-Rathlou N-H, et al. The influence of body posture on lithium clearance. Scand J Clin Lab Invest 1988; 48: 509–12PubMedGoogle Scholar
  28. 28.
    Kirchner KA. Lithium as a marker for proximal tubule delivery during low salt intake and diuretic infusion. Am J Physiol 1987; 253: F188–96PubMedGoogle Scholar
  29. 29.
    Macfie AC. Lithium poisoning precipitated by diuretics [letter]. BMJ 1975; 1: 516PubMedGoogle Scholar
  30. 30.
    Solomon JG. Lithium toxicity precipitated by a diuretic. Psychosomatics 1980; 21: 425–9PubMedGoogle Scholar
  31. 31.
    Kerry RJ, Ludlow JM, Owen G. Lesson of the week — diuretics are dangerous with lithium. BMJ 1980; 281: 371PubMedGoogle Scholar
  32. 32.
    Levy ST, Forrest JN, Heninger GR. Lithium-induced diabetes insipidus: manic symptoms, brain and electrolyte correlates, and chlorothiazide treatment. Am J Psychiatry 1973; 130: 1014–8PubMedGoogle Scholar
  33. 33.
    Poust RI, Mallinger AG, Mallinger J, et al. Effect of chlorothiazide on the pharmacokinetics of lithium in plasma and erythrocytes. Psychopharmacol Commun 1976; 2: 273–84PubMedGoogle Scholar
  34. 34.
    Jefferson JW, Kalin NH. Serum lithium levels and long-term diuretic use. JAMA 1979; 241: 1134–6PubMedGoogle Scholar
  35. 35.
    Crabtree BL, Mack JE, Johnson CD, et al. Comparison of the effects of hydrochlorothiazide and furosemide on lithium disposition. Am J Psychiatry 1991; 148: 1060–3PubMedGoogle Scholar
  36. 36.
    Jakobsson B, Berg U. Effect of hydrochlorothiazide and indomethacin treatment on renal function in nephrogenic diabetes insipidus. Acta Paediatr 1994; 83: 522–5PubMedGoogle Scholar
  37. 37.
    Himmelhoch JM, Poust RI, Mallinger AG, et al. Adjustment of lithium dose during lithium-chlorothiazide therapy. Clin Pharmacol Ther 1977; 22: 225–7PubMedGoogle Scholar
  38. 38.
    Hertig HI, Dyson WL. Lithium toxicity enhanced by diuretics. N Engl J Med 1974; 290: 748–9Google Scholar
  39. 39.
    Oh TE. Frusemide and lithium toxicity. Anaesth Intensive Care 1977; 5: 60–2PubMedGoogle Scholar
  40. 40.
    Huang LG. Lithium intoxication and coadministration of a loop-diuretic [letter]. J Clin Psychopharmacol 1990; 10: 228PubMedGoogle Scholar
  41. 41.
    Steele TH, Dudgeon KL, Larmore CK. Pharmacological characterization of lithium reabsorption in the rat. J Pharmacol Exp Ther 1976; 196: 188–93PubMedGoogle Scholar
  42. 42.
    Shirley DG, Walter SJ, Sampson B. A micropuncture study of renal lithium reabsorption: effects of amiloride and furosemide. Am J Physiol 1992; 263: F1128–33PubMedGoogle Scholar
  43. 43.
    McNabb WR, Noormohamed FH, Brooks BA, et al. Renal action of piretanide and three other ‘loop’ diuretics. Clin Pharmacol Ther 1984; 35: 328–37PubMedGoogle Scholar
  44. 44.
    Atherton JC, Doyle A, Gee A, et al. Lithium clearance: modification by the loop of Henle in man. J Physiol 1991; 437: 377–91PubMedGoogle Scholar
  45. 45.
    Thomsen K, Schou M. Renal excretion in man. Am J Physiol 1968; 215: 823–7PubMedGoogle Scholar
  46. 46.
    Saffer D, Coppen A. Frusemide: a safe diuretic during lithium therapy? J Affect Disord 1983; 5: 289–92PubMedGoogle Scholar
  47. 47.
    Obek A. Mannitol infusions and lithium excretion [letter]. BMJ 1972; 4: 550PubMedGoogle Scholar
  48. 48.
    Shneerson JM. Acute lithium intoxication. Br J Clin Pract 1978; 32: 232, 237PubMedGoogle Scholar
  49. 49.
    Baer L, Platman SR, Kassir S, et al. Mechanisms of lithium handling and their relationship to mineralocorticoids: a disassociation between sodium and lithiumions. J Psychiatr Res 1971; 8: 91–105PubMedGoogle Scholar
  50. 50.
    Batlle DC, von Riotte AB, Gaviria M, et al. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med 1985; 312: 408–14PubMedGoogle Scholar
  51. 51.
    Kosten TR, Forrest JN. Treatment of severe lithium-induced polyuria with amiloride. Am J Psychiatry 1986; 143: 1563–8PubMedGoogle Scholar
  52. 52.
    Thomsen K, Leysac PP. Acute effects of various diuretics on lithium clearance. Renal Physiol 1986; 9: 1–8PubMedGoogle Scholar
  53. 53.
    Perry PJ, Calloway RA, Cook BL, et al. Theophylline precipitated alterations of lithium clearance. Acta Psychiatr Scand 1984; 69: 528–37PubMedGoogle Scholar
  54. 54.
    Holstad SG, Perry PJ, Kathol RG, et al. The effects of intravenous theophylline infusion on lithium clearance in normal subjects. Psychiatr Res 1988; 25: 203–11Google Scholar
  55. 55.
    Furlong FW. Possible psychiatric significance of excesssive coffee consumption. Can Psychiatr Assoc J 1975; 20: 577–83PubMedGoogle Scholar
  56. 56.
    Bikin D, Conrad KA, Mayersohn M. Lack of influence of caffeine and aspirin on lithium elimination [abstract]. Clin Res 1982; 30: 249AGoogle Scholar
  57. 57.
    Mester R, Toren P, Mizrachi I, et al. Caffeine withdrawal increases lithium blood levels. Biol Psychiatry 1995; 37: 348–50PubMedGoogle Scholar
  58. 58.
    Douste-Blazy P, Rostin M, Livarek B, et al. Angiotensin-con-verting enzyme inhibitors and lithium treatment [letter]. Lancet 1986; 1: 1448PubMedGoogle Scholar
  59. 59.
    Mahieu M, Houvenagel E, Leduc JJ, et al. Lithium inhibitors of converting-enzyme, an association to be avoided [letter]. Presse Med 1988; 17: 281PubMedGoogle Scholar
  60. 60.
    Pulik M, Lida H. Interaction between lithium and angiotensin-converting enzyme inhibitors [letter]. Presse Med 1988; 17: 755PubMedGoogle Scholar
  61. 61.
    Conrad AJ. Ace inhibitors and lithium toxicity. Mass Gen Hosp Newslett 1988; 2: 43Google Scholar
  62. 62.
    Navis GJ, de Jong PE, de Zeeuw D. Volume homeostasis, angiotensin-converting enzyme inhibition, and lithium therapy [letter]. Am J Med 1989; 86: 621PubMedGoogle Scholar
  63. 63.
    Drouet A, Bouvet O. Lithium et inhibitors de l’enzyme de conversion. Encephale 1990; 16: 51–2PubMedGoogle Scholar
  64. 64.
    Baldwin CM, Safferman AZ. A case of lisinopril-induced lithium toxicity. DICP 1990; 24: 946–7PubMedGoogle Scholar
  65. 65.
    Griffin JH, Hahn SM. Lisinopril-induced lithium toxicity [letter]. DICP 1991; 25: 101PubMedGoogle Scholar
  66. 66.
    Correa FJ, Eiser AR. Angiotensin-converting enzyme inhibitors and lithium toxicity. Am J Med 1992; 93: 108–9PubMedGoogle Scholar
  67. 67.
    Das Gupta K, Jefferson JW, Kobak KA, et al. The effect of enalopril on serum lithium levels in healthy men. J Clin Psychiatry 1992; 53: 398–400Google Scholar
  68. 68.
    Finley PR, O’Brien JG, Coleman RW. Lithium and angiotensin converting enzyme inhibitor drug interaction. J Clin Psychopharmacol 1995. In pressGoogle Scholar
  69. 69.
    Brunner HR, Waeber B, Nussberger J. Renal effects of converting enzyme inhibition. J Cardiovasc Pharmacol 1987; 9 Suppl. 3: 6–14Google Scholar
  70. 70.
    Ganong WF. The brain renin-angiotensin system. Ann Rev Physiol 1984; 46: 17–31Google Scholar
  71. 71.
    Mason NA. Angiotensin-converting enzyme inhibitors and renal function. DICP 1990; 24: 496–505PubMedGoogle Scholar
  72. 72.
    Valdiserri EV. A possible interaction between lithium and diltiazem: a case report. J Clin Psychiatry 1985; 46: 540–1PubMedGoogle Scholar
  73. 73.
    Dubovsky SI, Franks RD, Allen S. Verapamil: a new antimanic drug with potential interactions with lithium. J Clin Psychiatry 1987; 48: 371–2PubMedGoogle Scholar
  74. 74.
    Price WA, Shalley JE. Lithium-verapamil toxicity in the elderly. J Am Geriatr Soc 1987; 35: 177–8PubMedGoogle Scholar
  75. 75.
    Binder EF, Cayabyab L, Ritchie DJ, et al. Psychosis and a possible diltiazem-lithium interaction. Arch Intern Med 1991; 151: 373–4PubMedGoogle Scholar
  76. 76.
    Wright BA, Jarrett DB. Lithium and calcium channel blockers: possible neurotoxicity. Biol Psychiatry 1991; 30: 635–6PubMedGoogle Scholar
  77. 77.
    Jacobsen FM, Sack DA, James SP. Delirium induced by verapamil. Am J Psychiatry 1987; 144: 248PubMedGoogle Scholar
  78. 78.
    Bushe CJ. Organic psychosis caused by diltiazem. J R Soc Med 1988; 81: 296–7Google Scholar
  79. 79.
    Bruun NE, Ibsen H, Skott P. Lithium clearance and renal tubular sodium handling during acute and long-term nifedipine treatment in essential hypertension. Clin Sci 1988; 75: 609–13PubMedGoogle Scholar
  80. 80.
    Leftwich R, Walker R, Smigel M, et al. Indomethacin is antidiuretic in lithium-induced diabetes insipidus [abstract]. Clin Res 1977; 25: 272AGoogle Scholar
  81. 81.
    Leftwich RB, Walker LA, Ragheb M, et al. Inhibition of prostaglandin synthesis increases plasma lithium levels [abstract]. Clin Res 1978; 26: 219AGoogle Scholar
  82. 82.
    Frolich JC, Leftwich R, Ragheb M, et al. Indomethacin increases plasma lithium. BMJ 1979; 1: 1115–6PubMedGoogle Scholar
  83. 83.
    Reimann IW, Diener U, Frolich JC. Indomethacin but not aspirin increases plasma lithium ion levels. Arch Gen Psychiatry 1983; 40: 283–6PubMedGoogle Scholar
  84. 84.
    Ragheb M. Ibuprofen can increase serum lithium level in lithium-treated patients. J Clin Psychiatry 1987; 48: 161–3PubMedGoogle Scholar
  85. 85.
    Reimann IG, Frolich JC. Effect of diclofenac on lithium kinetics. Clin Pharmacol Ther 1981; 30: 348–52PubMedGoogle Scholar
  86. 86.
    Ragheb M, Powell AL. Lithium interaction with sulindac and naproxen. J Clin Psychopharmacol 1986; 6: 150–4PubMedGoogle Scholar
  87. 87.
    Ragheb MA. Aspirin does not significantly effect patients’ serum lithium levels [letter]. J Clin Psychiatry 1987; 48: 425PubMedGoogle Scholar
  88. 88.
    Ragheb MA, Powell RA. Failure of sulindac to increase serum lithium levels. J Clin Psychiatry 1986; 47: 33–4PubMedGoogle Scholar
  89. 89.
    Ayd FJ. Lithium-mefenamic acid interaction. Int Drug Ther Newsl 1982; 17: 16Google Scholar
  90. 90.
    Shelley RK. Lithium toxicity and mefenamic acid: a possible interaction and the role of prostaglandin inhibition. Br J Psychiatry 1987; 151: 847–8PubMedGoogle Scholar
  91. 91.
    Kerry RJ, Owen G, Michaelson S. Possible toxic interaction between lithium and piroxicam. Lancet 1983; 1: 418–9PubMedGoogle Scholar
  92. 92.
    Nadarajah J, Stein GS. Piroxicam induced lithium toxicity [letter]. Ann Rheum Dis 1985; 44: 502PubMedGoogle Scholar
  93. 93.
    Iyer V. Ketorolac induced lithium toxicity. Headache 1994; 34: 442–4PubMedGoogle Scholar
  94. 94.
    Ragheb M. The clinical significance of lithium-nonsteroidal anti-inflammatory drug interaction. J Clin Psychopharmacol 1990; 10: 350–4PubMedGoogle Scholar
  95. 95.
    Prakash R, Kelwala S, Ban TA. Neurotoxicity with combined administration of lithium and a neuroleptic. Compr Psychiatry 1982; 23: 567–71PubMedGoogle Scholar
  96. 96.
    Cohen WJ, Cohen NH. Lithium carbonate, haloperidol and irreversible brain damage. JAMA 1974; 230: 1283–7PubMedGoogle Scholar
  97. 97.
    Marhold J, Zimanova J, Lachman M, et al. To the incompatibility of haloperidol with lithium salts. Acta Nerv Super 1974; 16: 199–200Google Scholar
  98. 98.
    Thornton WE, Pray BJ. Lithium intoxication: a report of 2 cases. Can Psychiatr Assoc J 1975; 20: 281–2PubMedGoogle Scholar
  99. 99.
    Spring G, Frankel M. New data on lithium and haloperidol incompatibility. Am J Psychiatry 1981; 138: 818–21PubMedGoogle Scholar
  100. 100.
    Spring G. Neurotoxicity with combined use of lithium and thi-oridazine. J Clin Psychiatry 1979; 40: 135–8PubMedGoogle Scholar
  101. 101.
    Alevizos B. Toxic reactions to lithium and neuroleptics [letter]. BrJ Psychiatry 1979; 135: 482Google Scholar
  102. 102.
    Spring G, Abrams R, Raylor MA. EEG observations in confirming neurotoxicity. Am J Psychiatry 1979; 136: 1099–100PubMedGoogle Scholar
  103. 103.
    Pope HG, Cole JO, Choras PT, et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 174: 493–5PubMedGoogle Scholar
  104. 104.
    Blake LM, Marks RC, Luchins DJ. Reversible neurological symptoms with clozapine and lithium. J Clin Psychopharmacol 1992; 12: 297–9PubMedGoogle Scholar
  105. 105.
    Swanson Jr CL, Price WA, McEvoy JP, et al. Effects of concomitant risperidone and lithium treatment [letter]. Am J Psychiatry 1995; 152(7): 1096PubMedGoogle Scholar
  106. 106.
    Goff DC, Baldessarini RJ. Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993; 13: 57–67PubMedGoogle Scholar
  107. 107.
    Ayd FJ. Lithium-haloperidol formulation: is it safe or hazardous? Int Drug Ther Newsl 1975; 10: 29–36Google Scholar
  108. 108.
    Baastrup PC, Hollnagel P, Sorensen P, et al. Adverse reactions in treatment with lithium carbonate and haloperidol. JAMA 1976; 236: 2645–6PubMedGoogle Scholar
  109. 109.
    Goldney RD, Spence ND. Safety of the combination of lithium and neuroleptic drugs. Am J Psychiatry 1986; 143: 882–4PubMedGoogle Scholar
  110. 110.
    Addonzio G, Roth SD, Stokes PE, et al. Increased extra-pyramidal symptoms with the addition of lithium to neuroleptics. J Nerv Ment Dis 1988; 176: 682–5Google Scholar
  111. 111.
    Miller F, Menninger J. Lithium-neuroleptic neurotoxicity is dose dependent. J Clin Psychopharmacol 1987; 7: 89–91PubMedGoogle Scholar
  112. 112.
    Kessel JB, Verghese C, Simpson G. Neurotoxicity related to lithium and neuroleptic combinations? A retrospective review. J Psychiatry Neurosci 1992; 17: 28–30PubMedGoogle Scholar
  113. 113.
    Pandey GN, Goel I, Davis JM. Effect of neuroleptic drugs on lithium uptake by human erythrocyte. Clin Pharmacol Ther 1979; 26: 96–102PubMedGoogle Scholar
  114. 114.
    von Knorring L, Smigan L, Perris C, et al. Lithium and neuroleptic drugs in combination — effect on lithium RBC/plasma ratio. Int Pharmacopsychiatry 1982; 17: 287–92Google Scholar
  115. 115.
    Schou M. Lithium and treatment-resistant depression: a review. Lithium 1990; 1: 3–8Google Scholar
  116. 116.
    Solomon JG. Seizures during lithium-amitriptyline therapy. Postgrad Med J 1979; 66: 145–6Google Scholar
  117. 117.
    Rosenberg PB, Pearlman CA. NMS-like syndrome with a lithium/doxepin combination. J Clin Psychopharmacol 1991; 11: 75–6PubMedGoogle Scholar
  118. 118.
    Austin LS, Arana GW, Melvin JA. Toxicity resulting from lithium augmentation of antidepressant therapy in elderly patients. J Clin Psychiatry 1990; 51: 344–5PubMedGoogle Scholar
  119. 119.
    Shah AK, McCloskey O. Case report: acute confusional state secondary to a combination of fluoxetine and lithium. Int J Geriatr Psychiatry 1992; 7: 687–8Google Scholar
  120. 120.
    Ohman R, Spigset O. Serotonin syndrome induced by fluvoxamine-lithium interaction. Pharmacopsychiatry 1993; 26: 263–4PubMedGoogle Scholar
  121. 121.
    Muly EC, McDonald W, Steffans D, et al. Serotonin syndrome induced by a combination of fluoxetine and lithium [letter]. Am J Psychiatry 1993; 150: 1565PubMedGoogle Scholar
  122. 122.
    Salama AA, Shafey M. A case of serious lithium toxicity induced by combined fluoxetine and lithium carbonate [letter]. Am J Psychiatry 1989; 146: 278PubMedGoogle Scholar
  123. 123.
    Wilner KD, Lazar JD, Von Deutsch DA, et al. The effects of sertraline on steady state lithium levels and renal clearance in man [abstract]. Biol Psychiatry 1991; 29: 354SGoogle Scholar
  124. 124.
    Hendrickx B, Flores M. A controlled pilot study of the combination of fluvoxamine and lithium. Curr Ther Res 1991; 49: 106–10Google Scholar
  125. 125.
    Data on file. SmithKline Beecham Pharmaceuticals, Philadelphia, 1993Google Scholar
  126. 126.
    Gram LF, Hansen MG, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imipramine and lithium. Ther Drug Monit 1993; 15: 18–24PubMedGoogle Scholar
  127. 127.
    Omura F, Kishimoto A, Tsutsui T, et al. Combined therapy of lithium and carbamazepine in bipolar affective disorders. Folia Psychiatr Neurol Jpn 1984; 38: 401–2Google Scholar
  128. 128.
    Post RM, Kramlinger K, Uhde TW. Carbamazepine-lithium combination: clinical efficacy and side effects. Int Drug Ther Newsl 1987; 22: 5–8Google Scholar
  129. 129.
    Chaudhry RP, Waters BGH. Lithium and carbamazepine interaction: possible neurotoxicity. J Clin Psychiatry 1983; 44: 30–1PubMedGoogle Scholar
  130. 130.
    Shukla S, Godwin CD, Long EB, et al. Lithium-carbamazepine neurotoxicity and risk factors. Am J Psychiatry 1984; 141: 1604–6PubMedGoogle Scholar
  131. 131.
    Price WA, Zimmer B. Lithium-carbamazepine neurotoxicity in the elderly. J Am Geriatr Soc 1985; 33: 876–7PubMedGoogle Scholar
  132. 132.
    Ghose K. Effect of carbamazepine in polyuria associated with lithium therapy. Pharmacopsychiatry 1978; 11: 241–5Google Scholar
  133. 133.
    Rybakowski JK, Lehman W, Kanarkowski R, et al. Possible pharmacokinetic interaction of lithium and carbamazepine. Lithium 1991; 2: 183–4Google Scholar
  134. 134.
    Yang YY, Dong HC. Influence of carbamazepine on lithium ratio in healthy volunteers: an in vitro method. Clin Neuropharmacol 1993; 16: 216–9PubMedGoogle Scholar
  135. 135.
    McGinness J, Kishimoto A, Hollister LE. Avoiding toxicity with lithium-carbamazepine combination. Psychopharmacol Bull 1990; 26: 181–4PubMedGoogle Scholar
  136. 136.
    Shopsin D, Johnson G, Gershon S. Neurotoxicity with lithium: differential drug responsiveness. Int Pharmacopsychiatry 1970; 5: 170–82Google Scholar
  137. 137.
    Speirs J, Hirsch SR. Severe lithium toxicity with ‘normal’ serum concentrations. BMJ 1978; 1: 815–6PubMedGoogle Scholar
  138. 138.
    MacCallum WAG. Interaction of lithium and phenytoin. BMJ 1980; 280: 610–1PubMedGoogle Scholar
  139. 139.
    Salem RB, Director K, Muniz CE. Ataxia as the primary symptom of lithium toxicity. Drug Intell Clin Pharm 1980; 14: 622–3Google Scholar
  140. 140.
    Graham-Smith DG, Green AR. The role of brain 5-hydroxy-tryptamine in the hyperactivity produced by rats by lithium and monoamine oxidase inhibitors. Br J Pharmacol 1974; 52: 19–26Google Scholar
  141. 141.
    Green AR, Graham-Smith DG. The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function. Neuropharmacology 1975; 14: 107–13PubMedGoogle Scholar
  142. 142.
    Borden H, Clarke MT, Katz H. The use of pancuronium bromide in patients receiving lithium carbonate. Can Aneasth Soc J 1974; 21: 79–82Google Scholar
  143. 143.
    Hill GE, Wong KC, Hodges MR. Potentiation of succinylcholine neuromuscular blockade by lithium carbonate. Anesthesiology 1976; 44: 439–42PubMedGoogle Scholar
  144. 144.
    Whittaker M, Spencer R. Plasma cholinesterase variants in patients receiving lithium therapy. Clin Chim Acta 1977; 75: 421–5PubMedGoogle Scholar
  145. 145.
    Arthur RK. Lithium levels and ‘Soda Bic’ [letter]. Med J Aust 1975; 2: 918PubMedGoogle Scholar
  146. 146.
    McSwiggan C. Interaction of lithium and bicarbonate. Med J Aust 1978; 1: 38–9PubMedGoogle Scholar
  147. 147.
    Holstad HG, Perry PJ, Kathol RG, et al. The effects of i.v. theophylline infusion versus i.v. sodium bicarbonate infusion on lithium clearance in normal subjects [reprint]. Psychiatr Res 1988; 25: 203–11Google Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Patrick R. Finley
    • 1
    • 2
  • M. Dhyanne Warner
    • 3
  • Cecilia A. Peabody
    • 1
  1. 1.Palo Alto Veterans Affairs Health Care System, Menlo Park DivisionMenlo ParkUSA
  2. 2.University of CaliforniaSan FranciscoUSA
  3. 3.Stanford UniversityStanfordUSA

Personalised recommendations